Plaque Psoriasis - Articles and news items

Sandoz proposed biosimilars recommended for EU approval

Industry news / 25 April 2017 / Niamh Marriott, Junior Editor

CHMP has adopted positive opinions, separately recommending the approval of both Sandoz’s biosimilar rituximab and biosimilar etanercept in Europe…

Suicidal ideation

FDA approves new psoriasis drug that induced suicide in trial

Industry news / 17 February 2017 / Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light […]


EMA to review Janssen’s plaque psoriasis monoclonal antibody

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development…

Novartis wins “Discovery of the Decade” and “Best Biotechnology Product” awards

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

Novartis has been awarded the 2016 Prix Galien USA Award “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec, as well as…

Novartis’ plaque psoriasis drug keeps skin clear 4 years post treatment

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

The aim of Novartis’ plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4…

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...